Blinatumomab, a bispecific T-cell engaging (BiTE) antibody, targets CD19+ B cells and CD3+ T cells, redirecting cytotoxic T cells to recognize and eliminate CD19+ B cells, including those in B-ALL (12, 13). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.